

# Hyaluronidase Market Growth, Trends & Forecast 2025 | DataM Intelligence

*Hyaluronidase Market involves enzymes used to enhance drug absorption and treat conditions like edema and fibrosis.*



The infographic features the DataM Intelligence logo at the top left. The main title is 'Hyaluronidase Market'. Below the title is a photograph of a person's face with a purple-gloved hand holding a syringe near their lips. To the right of the photo, it states 'CAGR of 8%' and 'Key players:' followed by a list of companies: PrimaPharma, Inc., Amphastar Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Halozyme, Inc., Sun Pharmaceutical Industries Ltd, and CooperSurgical Fertility. At the bottom left of the infographic is an email icon and the address 'Info@datamintelligence.com'. The title 'Hyaluronidase Market' is repeated at the bottom of the infographic.

AUSTIN, TX, UNITED STATES, May 22, 2025 /EINPresswire.com/ -- Market Overview:

[Hyaluronidase Market](#) is an enzyme that helps break down hyaluronic acid, allowing injectable drugs to be absorbed and distributed more effectively in the body. It is widely utilized in a variety of medical sectors, particularly to transition treatments from intravenous to subcutaneous ways, making the procedure more comfortable for patients and manageable. In recent years, its application has spread into cosmetic medicine, where it plays an important role in resolving concerns with dermal fillers, resulting in an increase in its popularity and demand.

Download Sample Report Here: <https://www.datamintelligence.com/download-sample/hyaluronidase-market>

## Key Market Drivers and Opportunities:

**Aesthetic Medicine Boom:** The rising popularity of non-surgical cosmetic procedures has escalated the demand for hyaluronidase, especially in correcting hyaluronic acid-based filler complications.

**Advancements in Oncology Treatments:** Hyaluronidase's ability to enhance the permeability of connective tissues has been leveraged to improve the efficacy of chemotherapeutic agents, offering promising avenues in cancer treatment protocols.



The Hyaluronidase Market is growing due to rising aesthetic procedures, improved drug absorption, and increased demand in oncology and ophthalmology.

”

*DataM Intelligence*

Regenerative Medicine Applications: Its role in preparing tissues for transplantation and improving therapeutic drug delivery positions hyaluronidase as a valuable component in regenerative medicine.

Market Segmentation:

By Type:

Animal-derived Hyaluronidase

Synthetic Hyaluronidase

By Application:

Dermatology

Chemotherapy

Ophthalmology

Plastic Surgery

Others

By End-user:

Hospital

Clinics

Research Centers

Others

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East and Africa

Geographical Market Share:

North America emerged as the leading region in the global hyaluronidase market in 2023, holding around 38% of the total revenue share. This regional dominance is primarily attributed to the strong presence of key pharmaceutical companies, a well-established healthcare infrastructure, and a high uptake of aesthetic procedures.

The Asia Pacific region is expected to register the highest growth rate over the forecast period, with a projected CAGR of 9.3%. The region's rapid expansion is fueled by the rise in medical tourism, growing awareness of aesthetic treatments, and ongoing technological innovations,

particularly in countries such as South Korea and Japan.

Leading Market Players:

Prominent companies shaping the hyaluronidase market landscape include:

PrimaPharma, Inc  
Amphastar Pharmaceuticals, Inc.  
Bausch & Lomb Incorporated  
Halozyme, Inc.  
Sun Pharmaceutical Industries Ltd  
STEMCELL Technologies, Inc.  
CooperSurgical Fertility  
Genomic Solutions Revance  
Shreya Life Sciences Pvt. Ltd.  
Halozyme, Inc

These companies are actively engaged in strategic collaborations, product launches, and research initiatives to enhance their market presence and address the evolving needs of the healthcare sector.

Recent Developments in the USA and Japan:

United States:

In September 2024, the U.S. Food and Drug Administration (FDA) approved Ocrevus Zunovo, a combination therapy of ocrelizumab and hyaluronidase, for the treatment of multiple sclerosis (MS). This approval introduces a subcutaneous administration option, providing patients with a more convenient alternative to traditional intravenous delivery.

Regulatory Challenges Impacting Market Dynamics: In May 2025, Halozyme Therapeutics experienced a significant stock decline following new Medicare guidelines that could expedite price negotiations for combination drugs utilizing hyaluronidase, potentially affecting the company's revenue model.

Japan:

Advancements in Recombinant Hyaluronidase: Alteogen Inc., a South Korean biotech firm, has developed and patented a recombinant human hyaluronidase protein, marking significant progress in the field and expanding potential applications in Japan and beyond.

In January 2023, Alteogen Inc. entered into an exclusive licensing agreement with Sandoz AG, giving Sandoz the rights to utilize Alteogen's innovative hyaluronidase technology, ALT-B4. This

technology is designed to enhance the development and commercialization of subcutaneous biosimilar products. The partnership is anticipated to significantly influence the biosimilar market, particularly in Japan.

Stay informed with the latest industry insights-start your subscription now:

<https://www.datamintelligence.com/reports-subscription>

Conclusion:

The hyaluronidase market is on a robust growth trajectory, driven by its expanding applications in medical and aesthetic fields, technological innovations, and strategic industry collaborations. As the demand for minimally invasive procedures and efficient drug delivery systems continues to rise, hyaluronidase's role in modern healthcare is set to become increasingly pivotal.

Related Reports:

[Hypothalamic Obesity Treatment Market](#)

[Scopolamine Market](#)

Sai Kiran

DataM Intelligence 4Market Research

+1 877 441 4866

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/815075816>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.